Navidea tumbles on extended US FDA review for radioactive tracing agent
This article was originally published in Clinica
Executive Summary
Shares of Navidea Biopharmaceuticals, formerly known as Neoprobe, tumbled as low as 39 cents, down 12%, on 3 April, after the Dublin, Ohio-based firm said the US FDA extended by three months the Prescription Drug User Fee Act (PDUFA) action date for the new drug application (NDA) for the company's radioactive diagnostic tracing agent Lymphoseek (tilmanocept). The radiotracer is designed for use in intraoperative lymphatic mapping (ILM), a surgical oncology procedure used primarily in patients with breast cancer and melanoma to determine if disease has spread to the lymph nodes.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.